Aegerion Pharmaceuticals (AEGR) Securities Class Action Notice
A class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) securities between March 15, 2012 and January 9, 2014 (the “Class Period”).
Allegations in the Complaint
The complaint alleges that Aegerion and certain of its officers made materially false and/or misleading statements and/or failed to disclose important information to investors.
Specifically, it is alleged that:
- Aegerion marketed its drug JUXTAPID in violation of the Federal Food, Drug, and Cosmetic Act
- The Company’s marketing practices exposed it to heightened regulatory scrutiny by the U.S. Food and Drug Administration (FDA) and other governmental authorities
- Statements concerning the Company’s business, operations, and prospects were materially false and misleading
DOJ Subpoena and Stock Price Decline
On January 9, 2014, Aegerion announced that it had received a subpoena from the United States Department of Justice, represented by the U.S. Attorney’s Office in Boston, Massachusetts. The subpoena requested documents relating to the Company’s marketing and sale of JUXTAPID in the United States.
Following this announcement:
- Shares of Aegerion declined $7.98 per share
- The stock fell nearly 11%
- Shares closed at $65.77 on January 10, 2014
- Trading volume was unusually heavy
Potential Investor Claims
Wites & Rogers is seeking to uncover additional information regarding the reported loss of shareholder value and potential claims on behalf of investors.
If you purchased Aegerion Pharmaceuticals securities between March 15, 2012 and January 9, 2014, you may have legal rights under federal securities laws.
In securities class actions, one investor may seek to serve as Lead Plaintiff on behalf of the class.
Contact Information
If you would like to discuss your rights or potential involvement as a lead plaintiff, contact Wites & Rogers:
info@witeslaw.com
1 (866) 277-8631
Consultations are confidential.
